Xenetic Biosciences Stock (NASDAQ:XBIO)
Previous Close
$4.08
52W Range
$2.78 - $5.20
50D Avg
$4.15
200D Avg
$3.99
Market Cap
$6.48M
Avg Vol (3M)
$22.05K
Beta
2.26
Div Yield
-
XBIO Company Profile
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
XBIO Performance
Peer Comparison
| Ticker | Company |
|---|---|
| RNAZ | TransCode Therapeutics, Inc. |
| TNXP | Tonix Pharmaceuticals Holding Corp. |
| ZVSA | ZyVersa Therapeutics, Inc. |
| GOVX | GeoVax Labs, Inc. |
| DRUG | Bright Minds Biosciences Inc. |
| PHIO | Phio Pharmaceuticals Corp. |
| ATNF | 180 Life Sciences Corp. |
| VRAX | Virax Biolabs Group Limited |
| IMMX | Immix Biopharma, Inc. |
| REVB | Revelation Biosciences, Inc. |
| SONN | Sonnet BioTherapeutics Holdings, Inc. |
| ZURA | Zura Bio Limited |
| ENVB | Enveric Biosciences, Inc. |
| PALI | Palisade Bio, Inc. |